Editorial |

Immunosuppression and Skin Cancer:  Pathogenetic Insights, Therapeutic Challenges, and Opportunities for Innovation

Clark C. Otley, MD
Arch Dermatol. 2002;138(6):827-828. doi:10.1001/archderm.138.6.827.
Text Size: A A A
Published online


THE PAST 30 years have seen unprecedented growth in the numbers of immunosuppressed patients, with iatrogenic and disease-related immunosuppression. Approximately 100 000 US citizens undergo long-term immunosuppression to preserve life-sustaining solid organ allografts. Worldwide, 36.1 million people are estimated to be living with the human immunodeficiency virus (HIV) or the acquired immunodeficiency syndrome. Chronic lymphocytic leukemia (CLL) affects approximately 81 000 patients per year in the United States, resulting in a prolonged immunocompromised status. To a lesser degree, patients with inflammatory disorders of the cutaneous and musculoskeletal systems may undergo long-term immunosuppression with therapeutic medications. Finally, we are entering an era of exploration in the use of biologic response modifiers and antibody-mediated immunomodulation with unknown long-term effects.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 10

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles